DEF: Milestone Pharmaceuticals Sets Date for 2025 Annual Shareholder Meeting, Proposes Equity Incentive Plan Changes

Milestone Pharmaceuticals will hold its 2025 Annual Meeting of Shareholders virtually on June 10, 2025, to vote on director elections, auditor ratification, an equity incentive plan amendment, and executive compensation.

Summary

• Milestone Pharmaceuticals Inc. will hold its 2025 Annual Meeting of Shareholders on June 10, 2025, at 11:00 a.m. Eastern Time, via a virtual meeting portal.
• Shareholders will vote on several proposals, including the election of eight directors, ratification of PricewaterhouseCoopers LLP as the company's auditor, and approval of an amendment to the 2019 Equity Incentive Plan.
• The proposed amendment to the 2019 Equity Incentive Plan includes removing the evergreen provision and increasing the number of shares authorized for issuance by 4,000,000 shares.
• There will also be non-binding advisory votes on executive compensation and the frequency of future advisory votes on executive compensation.
• The record date for the Annual Meeting is April 15, 2025.
• The Board of Directors recommends voting FOR all director nominees, FOR the ratification of the auditor, FOR the approval of the equity incentive plan amendment, FOR the advisory vote on executive compensation, and ONE YEAR for the frequency of future advisory votes on executive compensation.

Sentiment

Score: 6

Explanation: The document is a standard proxy statement, so the sentiment is neutral. It contains routine information about the company's governance and upcoming shareholder meeting.

Positives

• The company is committed to ongoing shareholder engagement.
• The board is composed of mostly independent directors.
• The company has a robust code of business conduct and ethics.
• The company prohibits insiders from pledging securities or purchasing on margin.
• The company has a clawback policy in place.

Negatives

• 100% of the awards outstanding under the Plan were underwater, or trading below their strike price, as of April 15, 2025.

Risks

• The company's ability to obtain a deduction for future payments under the Amended 2019 Plan could be limited by the golden parachute rules of Section 280G of the Code.
• If the Amended 2019 Plan is not approved, the Board of Directors believes that we will not have sufficient shares available under the 2019 Plan to make grants to help us retain top employees and other service providers and, unless we increase our Inducement Plan without the approval of our shareholders (pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules), we will not be able to use equity compensation awards to attract new employees.

Future Outlook

The company intends to grant future equity awards under the Amended 2019 Plan in amounts that are reasonable and based on market data prepared by the independent compensation consultant to the Compensation Committee.

Management Comments

• 'We appreciate your continued ownership of Milestone shares and your support,' said Joseph Oliveto, President and Chief Executive Officer.

Industry Context

The document reflects standard corporate governance practices for publicly traded companies, including shareholder meetings, director elections, and executive compensation disclosures.

Comparison to Industry Standards

• The document does not contain enough information to make a detailed comparison to industry standards.
• The document does not contain enough information to make a detailed comparison to global benchmarks.
• The document does not contain enough information to make a detailed comparison to specific comparible companies, projects, and results.

Related Party Transactions

• The company is party to a third amended and restated registration rights agreement, dated October 15, 2018, with certain holders of common shares issued upon conversion of preferred shares.
• On July 14, 2024, the company entered into a Cooperation Agreement with Alta Fundamental Advisors LLC regarding the membership and composition of our Board.
• On March 27, 2023, the company entered into a Purchase and Sale Agreement (the Royalty Purchase Agreement) with RTW Investments, LP and certain of its affiliates (collectively, RTW).
• On March 27, 2023, the company entered into a Note Purchase Agreement (as amended, the Note Purchase Agreement) with RTW.
• On March 4, 2024, the company issued and sold to certain institutional and accredited investors (the Investors) in a private placement (the Private Placement) an aggregate of 19,666,667 of the Companys common shares (the Shares), without par value, in addition to pre-funded warrants (the Private Placement Pre-Funded Warrants) to purchase an aggregate of 3,333,333 shares of common stock.

Stakeholder Impact

• Shareholders have the opportunity to vote on key company matters.
• Employees may be affected by changes to the equity incentive plan.
• The outcome of the votes could influence the company's strategic direction and financial performance.

Next Steps

• Shareholders are encouraged to vote on the proposals outlined in the proxy statement.
• The company will file a Registration Statement on Form S-8 with the SEC with respect to the shares of the Companys common stock to be registered pursuant to the Amended 2019 Plan, as soon as reasonably practicable following shareholder approval.

Key Dates

Keywords

Annual Meeting, Shareholders, Proxy Statement, Board of Directors, Equity Incentive Plan, Executive Compensation, Director Election, Auditor Ratification, Corporate Governance